Rankings
▼
Calendar
SUPN
Supernus Pharmaceuticals, Inc.
$3B
Q4 2016 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$62M
Gross Profit
$59M
94.0% margin
Operating Income
$16M
26.1% margin
Net Income
$14M
23.0% margin
EPS (Diluted)
$0.26
QoQ Revenue Growth
+9.8%
Cash Flow
Operating Cash Flow
$25M
Free Cash Flow
$25M
Stock-Based Comp.
$1M
Balance Sheet
Total Assets
$310M
Total Liabilities
$118M
Stockholders' Equity
$192M
Cash & Equivalents
$90M
← FY 2016
All Quarters
Q1 2017 →
SUPN Q4 2016 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
